Soligenix开始第3阶段的HyBryte试验,这是对早期皮肤淋巴瘤的一种新治疗。 Soligenix starts Phase 3 trial for HyBryte, a new treatment for early-stage skin lymphoma.

Soligenix已开始了名为 " FLASH2 " 的第三阶段研究,以测试HyBryte,一种用于早期切片T细胞淋巴瘤的合成高血激素治疗法(CTCL)。 Soligenix has begun a Phase 3 study called FLASH2 to test HyBryte, a synthetic hypericin treatment for early-stage cutaneous T-cell lymphoma (CTCL). 试验将招募美国和欧洲的80名患者, 评估药物在持续治疗18周的有效性. The trial will enroll about 80 patients across the U.S. and Europe, assessing the drug's efficacy over 18 weeks of continuous treatment. 这项研究是继早期成功试验之后进行的,旨在证实HyBryte在不中断治疗的情况下的有效性和安全性,有可能为可能导致二次癌症的现有疗法提供更安全的替代方法。 This study follows a successful earlier trial and aims to confirm HyBryte's effectiveness and safety without breaks in treatment, potentially offering a safer alternative to existing therapies that can cause secondary cancers.